Here's Why GlycoMimetics Could Become a Takeover Target
Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next year could send shares even higher next year.
The company plans to begin a phase 3 study of GMI-1271 by the middle of 2018, and in the second half of 2018, data is expected from a phase 3 study evaluating GlycoMimetics and Pfizer's (NYSE: PFE) sickle-cell disease drug, rivipansel.
The potential to improve AML treatment and improve the lives of sickle-cell disease patients could make this company an intriguing takeover target, so let's learn more about GlycoMimetics' story.
Source: Fool.com
Glycomimetics Inc. Aktie
0,15 €
-6,25 %
Bei Glycomimetics Inc. herrscht Gleichgewicht zwischen 4 Buy- und 5 Sell-Einschätzungen.
Ein unerwartetes Potenzial von 4610.63% für Glycomimetics Inc., gegeben ein Kursziel von 7 €, das über dem aktuellen Kurs von 0.15 € liegt.
